One hundred years ago, when Abigail Geisinger, the widow of an iron mining magnate, founded the 63-bed George F. Geisinger Memorial Hospital in Danville, Pa., she told the chief surgeon: “Make my hospital right; make it the best.”
Fourteen hospitals operated by Franklin, Tenn.-based Iasis Healthcare are under scrutiny in the yearslong nationwide investigation into the suspected overuse of implantable defibrillators.
Pack-a-day smokers in the federal health program now have access to low-dose CT scans for the early detection of lung cancer even as experts continue to debate whether the benefits are worth the cost and risk of false positives.
Getting big-ticket medical devices, drugs and procedures covered by Medicare is getting harder, according to a new analysis of national coverage decisions between 1999 and 2012. The CMS was about 20 times more likely to say no in the more recent years.
Public interest and media attention around the Food and Drug Administration's proposal to regulate laboratory-developed tests (LDTs) has gone from a slow burn to steady flame in recent weeks. That is a good thing.
Democrats on the House Energy & Commerce Committee have withdrawn support from legislation that would loosen regulatory requirements on a broad range of new healthcare technologies, sources close to the legislative discussions say.
Michael Mussallem, chairman and CEO of Irvine, Calif.-based devicemaker Edwards Lifesciences, discusses the company's plans, how his firm demonstrates the value of its products to health systems and the prospects for repeal of the medical-device tax. He spoke with Modern Healthcare reporter Jaimy...
The CMS will continue ordering some drug and device manufacturers to collect evidence on how well their technologies work before giving its final approval on reimbursement.
Researchers and cost-control advocates are increasingly questioning drugs, devices and procedures that proved effective in clinical trials but don't achieve the same outcomes once widely deployed. Sometimes they perform worse than cheaper alternatives already on the market.
Those squat disinfecting robots that zap deadly pathogens seem to have more personality than expected.
There is an economic benefit for payers and patients when using tomosynthesis, a more advanced form of mammography, to screen women for breast cancer at a time when adoption of the new technology is growing, researchers conclude in a study.
A Food and Drug Administration proposal to regulate laboratory-developed tests could upend a clinical sector that provides thousands of tests to healthcare providers every day, raising costs and potentially limiting patient access, detractors say.